Flow Health Science

What Flow Health Science does

Flow Health Science (legal entity: Flow Science Holdings Ltd., registered in England & Wales, No. 16667576) is a London-based, privately-held functional nutrition company that develops clinically-proven advanced foods targeting specific metabolic and chronic health needs. It employs a documented three-stage development process (Target, Build, Prove) combining insights from metabolic science and clinical medicine with food technology, and operates a disclosed pipeline spanning diabetes hypoglycemia, performance, women's health, fatigue, and cardiovascular health. Its commercial surface today is anchored by Klario (FLO23011), a ready-to-drink formulation launched in 2026 that delivers 15g of fast-acting carbohydrate combined with the ketone body beta-hydroxybutyrate (BHB), positioned as an upgrade to standard glucose-only hypo treatments.

The company's technical core is MESH™ (Multi-Energy Substrate for Hypoglycaemia), a proprietary formulation architecture combining glucose with BHB and other adaptive energy substrates to address the 'brain energy bottleneck' — a peer-reviewed (Diabetes, Obesity and Metabolism) mechanism attributing incomplete hypo recovery to NAD+ depletion impairing neuronal glucose metabolism even after blood glucose normalizes. Klario's clinical evidence base is unusually deep for an early-stage nutrition company: a 12-week randomized, open-label crossover trial in 12 adults with Type 1 diabetes covering 1,032 hypoglycaemia episodes, plus a mechanistic translational analysis. Reported outcomes include a 27% relative reduction in recurrent hypoglycaemic episodes, a 7.1% Time-in-Range improvement in the 2-hour post-hypo window, and 75% of users reporting a faster return to normal daily activities.

Commercially, Flow Health Science operates a direct-to-consumer model selling Klario exclusively through its own e-commerce storefront at myklario.com, primarily targeting adults with insulin-treated Type 1 diabetes in the UK/European market. Pricing is not publicly disclosed. The go-to-market leans on scientific credibility: peer-reviewed publications, presentations at major diabetes congresses (ADA Scientific Sessions 2026, DUKPC 2026, EASD), patient-facing events such as Klario Results Day, ADA Innovation Challenge finalist status, and the 2026 World Food Innovation Awards 'Best Health Innovation' win from a 100+ brand field spanning 28 countries. The company is led by CEO Georgia Myers, Chairman Richard Littlewood, and Chief Strategy & Business Officer Tara Lumley, with an advisory board including Prof. David Russell-Jones and Prof. Mike Laffan. No funding rounds, revenue figures, headcount, partnerships, or M&A activity are disclosed in available sources.

Name

Flow Health Science

Legal name

FLOW SCIENCE HOLDINGS LTD.

Website

https://flowhealthscience.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Flow Health Science is a London-based functional nutrition company developing clinically-proven advanced foods for specific metabolic health needs. Its flagship product, Klario, is a glucose plus BHB ready-to-drink launched in 2026 for hypoglycemia recovery in adults with Type 1 diabetes, sold direct-to-consumer online.

Ownership category

akta.pro rank

Product category

Functional Nutrition

NAICS

Food (Health) Supplement Retailers (456191)

SIC

Bottled & Canned Soft Drinks & Carbonated Waters (2086)

akta.pro primary industry

Medical & Clinical Nutrition Beverage Production (Oral Nutritional Supplements) (AFAFAFAJ)

akta.pro secondary industry

Medical Nutrition & Meal Replacement (RTD, Bars, Powders) (CRADAGAN)

Keywords

• Functional nutrition
• Clinical nutrition products
• Diabetes management
• Hypoglycaemia recovery
• Advanced nutrition

Headquarters

HQ city

City Of London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel

Revenue model

1. Klario® Product Sales: Flow Health Science generates revenue through direct-to-consumer sales of its Klario® hypoglycaemia recovery drink via its e-commerce storefront at myklario.com. Klario was commercially launched in 2026 following clinical validation, representing the company's first revenue-generating product.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Flow Health Science develops, manufactures and commercializes clinically-proven functional nutrition products targeting specific health needs. Its flagship launched product, Klario (FLO23011), is a ready-to-drink multi-substrate formulation combining fast-acting glucose with beta-hydroxybutyrate (BHB) for hypoglycaemia recovery in adults with Type 1 diabetes, sold direct-to-consumer via myklario.com. A pipeline of additional products targets performance, women's health, fatigue, and cardiovascular health.

Product overview

Flow Health Science is a clinically-proven advanced nutrition company developing functional foods targeting specific health needs. The core launched product is Klario (FLO23011), a glucose plus beta-hydroxybutyrate (BHB) drink for hypoglycemia recovery in type 1 diabetes. The pipeline includes FLO25028 for performance and FLO25027 for women's health (both in Build phase), plus FLO26026 for fatigue and FLO26037 for cardiovascular health (both in Target phase), all following the company's three-stage Target-Build-Prove development process.

Differentiator

Problem solved

Functional benefit

Brands

• Klario: A novel combination treatment for complete recovery from hypoglycaemia in diabetes, clinically proven to be more effective than standard sugar products. Combines glucose with beta-hydroxybutyrate (BHB) for improved hypo recovery outcomes.

Products and services

• Klario (FLO23011) A glucose plus beta-hydroxybutyrate (BHB) adaptive energy drink clinically proven to improve recovery from hypoglycaemia in adults with Type 1 diabetes. Delivers 15g fast-acting carbohydrates with BHB for improved glycaemic control, reduced recurrence, and faster cognitive recovery compared to glucose-only treatments.

Quantifiable outcome

• 27% relative reduction in recurrent hypoglycaemic episodes vs. standard glucose-only treatment
• +6 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• Nutrisense: Nutrisense pairs CGM data with personalized nutrition coaching as a subscription DTC service. Comparable to Flow Health Science as an early-stage, evidence-led metabolic health platform intersecting glucose monitoring and nutrition intervention.
• Virta Health: Virta Health is a clinically validated, nutrition-led diabetes reversal program with published outcomes. It overlaps with Flow Health Science on using clinical evidence to address Type 2/Type 1 diabetes through nutrition, though its model is service-based rather than product-based.
• Signos: Signos combines CGM with AI-driven nutrition and weight management in a DTC subscription format. Comparable as a metabolic-health-focused, evidence-positioned early-stage company targeting the same glucose- and nutrition-aware consumer segment.

Direct peers

• ZOE: ZOE is a UK-based personalized nutrition company that pairs clinical science with a DTC subscription model. It overlaps with Flow Health Science on evidence-led functional nutrition targeting metabolic health and on UK/EU market positioning.
• Pendulum: Pendulum sells clinically validated microbiome and metabolic health products (e.g., glucose-control probiotics) direct-to-consumer. Comparable to Flow Health Science in combining clinical evidence, mechanism-based storytelling, and DTC distribution in metabolic health adjacencies.
• Levels Health: Levels combines continuous glucose monitoring data with a software/metabolic insights product for consumers. It is directly comparable as a metabolic-health-focused, evidence-led DTC platform intersecting glucose and nutrition.
• AG1 (Athletic Greens): AG1 is a premium, science-led daily nutritional drink sold via DTC subscription. Comparable to Flow Health Science on the model of a single, clinically positioned RTD functional nutrition SKU scaled through direct e-commerce.
• Huel: Huel is a UK-based, category-defining functional nutrition brand selling RTD meals and shakes DTC globally. It is comparable as a UK-headquartered, clinically-positioned, mass-market functional nutrition DTC operator.

Broad incumbents

• Nestlé Health Science: Nestlé Health Science is a global leader in medical nutrition with established diabetes and metabolic health brands. It is comparable as the most likely strategic acquirer and primary competitive benchmark for clinically validated nutrition products in diabetes.
• Abbott (Glucerna / Diabetes Care): Abbott sells Glucerna (medical nutrition for people with diabetes) and FreeStyle Libre (CGM) at global scale. Comparable as the dominant incumbent in diabetes-specific nutrition and adjacent glucose-monitoring ecosystem into which Klario would need to expand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/flowhealthscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flow Health Science